News at CenExel
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine
TLC590 showed faster and longer lasting pain relief than ropivacaine SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – October 21, 2019 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet...
CenExel Chief Scientific Advisor Todd Bertoch, MD, to Lead Session at Pain Therapeutics Summit 2019
SALT LAKE CITY, Sept. 23, 2019 /PRNewswire/ -- CenExel Clinical Research, Inc., ("CenExel" or the "Company") announced that Todd Bertoch, MD, Chief Scientic Advisor for CenExel and Chief Medical Ofcer for JBR Clinical Research, a CenExel Center of Excellence, will...
Todd Bertoch, MD, CenExel Chief Scientific Advisor, To Speak at BTIG Pain Management Forum
SALT LAKE CITY, Sept. 11, 2019 /PRNewswire/ -- CenExel Clinical Research, Inc., ("CenExel" or the "Company") announced that Todd Bertoch, MD, Chief Scientific Advisor for CenExel and Chief Medical Officer for JBR Clinical Research, a CenExel Center of...
CenExel Clinical Research’s Anaheim Clinical Trials Passes FDA, EMA & Japanese PMDA Inspections all Within 45 Days
Webster Capital-based CenExcel Clinical Research Inc. (CenExel) was formed in 2018 with the merger of JBR Clinical Research, a Salt Lake City facility specializing in analgesia research and vaccine testing, with ACMR, an Atlanta-based psychiatric research...
Contact Us
Ready to learn more?
Find out how our expertise can help you obtain your clinical research results, on-time and on-budget.
